Search Results

Australia’s Department of Health has issued import permits for Optimi’s MDMA and psilocybin capsules for use under the Authorised Prescriber Scheme

A new report by Bryter released today reveals where pharma can lead as patients turn to (and question) AI tools for mental health.

Biorasi , a leading global full-service contract research organization (CRO), announced today that they have selected IBM Watson Health (IBM) as a preferred vendor. This relationship with IBM Watson Health expands Biorasi’s capabilities in clinical trial execution and management through IBM’s Clinical Development (ICD) platform – a clinical data management system (CDMS) designed to help bring efficiency and speed to the clinica

Annual ranking introduces first measure of hospitals’ contributions to community health with a focus on equity, developed by IBM Watson Health in collaboration with Johns Hopkins Center for Health Equity and Bloomberg American Health Initiative at the Johns Hopkins Bloomberg School of Public Health

Australia’s largest private health insurer expands its AUD $10M psychotherapy program to cover psilocybin for Treatment-Resistant Depression, building on earlier MDMA coverage for PTSD

The Fortune/IBM Watson Health 50 Top Cardiovascular Hospitals winners demonstrate opportunities to potentially save thousands of additional lives and billions of dollars in costs